Alan F Schatzberg MD
Director, Stanford Mood Disorders Center. Professor, Department of Psychiatry and Behavioral Sciences Stanford University Medical Center.
Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-498-5710
Fax+1 650-498-5294
Dr. Schatzberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Harvard Medical SchoolResidency, Psychiatry, 1969 - 1972
Lenox Hill Hospital-Northwell HealthInternship, Transitional Year, 1968 - 1969
New York University School of MedicineClass of 1968
Certifications & Licensure
CA State Medical License 1974 - 2026
MA State Medical License 1969 - 2025
American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- Women's Health Castle Connolly, 2008
- Elected Member Institute of Medicine, 2003
- Join now to see all
Clinical Trials
- Age-Related Changes in Stress Hormone Regulation Start of enrollment: 2000 Dec 01
- Clinical and Biological Characteristics of Psychotic Depression Start of enrollment: 2005 Aug 01
- Genetics of Symptomatology and Treatment Response in Psychotic Major Depression Start of enrollment: 2003 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsEsketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.Konstantinos N Fountoulakis, Athanasios Saitis, Alan F Schatzberg
The American Journal of Psychiatry. 2025-03-01 - 1 citationsRedefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?Marjorie R Levinstein, Reece C Budinich, Jordi Bonaventura, Alan F Schatzberg, Carlos A Zarate Jr
The American Journal of Psychiatry. 2025-03-01 - A Stratified Precision Medicine Trial Targeting Selective Mechanisms of Alpha 2A Agonism as a Treatment for the Cognitive Biotype of Depression: The BIomarker Guided (...Leanne Williams, Laura Hack, Jenna Jubeir, Rachel Hilton, Leonardo Tozzi
Research Square. 2025-02-27
Journal Articles
- Splice-Break: Exploiting an RNA-Seq Splice Junction Algorithm to Discover Mitochondrial DNA Deletion Breakpoints and Analyses of Psychiatric DisordersFrancis S Lee, Alan F Schatzberg, Jack D Barchas, Virginia Kimonis, Elizabeth C Chao, Nucleic Acids Research
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
- American Psychiatric Association PublishingAlan Schatzberg, MD, National Institutes of Health
Press Mentions
Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input from New Clinical Advisory BoardMarch 3rd, 2025- Terence Ketter Dies at 74December 20th, 2024
- Magnus Medical Receives FDA Clearance for the SAINT Neuromodulation System for Non-Invasive, Individualized and Precise Treatment of Severe DepressionSeptember 6th, 2022
- Join now to see all
Grant Support
- The Career Development Institute for PsychiatryUNIVERSITY OF PITTSBURGH AT PITTSBURGH2011–2027
- A Biobehavioral research Training ProgramSTANFORD UNIVERSITY1994–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
